AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease
Open Access
- 16 March 2009
- journal article
- review article
- Published by Portland Press Ltd. in Clinical Science
- Vol. 116 (8), 607-620
- https://doi.org/10.1042/cs20080066
Abstract
AMPK (AMP-activated protein kinase) is a heterotrimetric enzyme that is expressed in many tissues, including the heart and vasculature, and plays a central role in the regulation of energy homoeostasis. It is activated in response to stresses that lead to an increase in the cellular AMP/ATP ratio caused either by inhibition of ATP production (i.e. anoxia or ischaemia) or by accelerating ATP consumption (i.e. muscle contraction or fasting). In the heart, AMPK activity increases during ischaemia and functions to sustain ATP, cardiac function and myocardial viability. There is increasing evidence that AMPK is implicated in the pathophysiology of cardiovascular and metabolic diseases. A principle mode of AMPK activation is phosphorylation by upstream kinases [e.g. LKB1 and CaMK (Ca(2+)/calmodulin-dependent protein kinase], which leads to direct effects on tissues and phosphorylation of various downstream kinases [e.g. eEF2 (eukaryotic elongation factor 2) kinase and p70 S6 kinase]. These upstream and downstream kinases of AMPK have fundamental roles in glucose metabolism, fatty acid oxidation, protein synthesis and tumour suppression; consequently, they have been implicated in cardiac ischaemia, arrhythmias and hypertrophy. Recent mechanistic studies have shown that AMPK has an important role in the mechanism of action of MF (metformin), TDZs (thiazolinediones) and statins. Increased understanding of the beneficial effects of AMPK activation provides the rationale for targeting AMPK in the development of new therapeutic strategies for cardiometabolic disease.Keywords
This publication has 142 references indexed in Scilit:
- Phosphorylation of LKB1 at Serine 428 by Protein Kinase C-ζ Is Required for Metformin-Enhanced Activation of the AMP-Activated Protein Kinase in Endothelial CellsCirculation, 2008
- Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitusAtherosclerosis, 2007
- AMP-activated protein kinase mediates VEGF-stimulated endothelial NO productionBiochemical and Biophysical Research Communications, 2007
- AMPK alterations in cardiac physiology and pathology: enemy or ally?The Journal of Physiology, 2006
- Activation of AMP‐activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disordersThe Journal of Physiology, 2006
- Metformin Prevents Alcohol-Induced Liver Injury in the Mouse: Critical Role of Plasminogen Activator Inhibitor-1Gastroenterology, 2006
- Thiazolidinediones inhibit TNFα induction of PAI-1 independent of PPARγ activationBiochemical and Biophysical Research Communications, 2005
- AICAR stimulates adiponectin and inhibits cytokines in adipose tissueBiochemical and Biophysical Research Communications, 2004
- Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinaseNature, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001